286 related articles for article (PubMed ID: 29509745)
1. Driving T-cell immunotherapy to solid tumors.
Garber K
Nat Biotechnol; 2018 Mar; 36(3):215-219. PubMed ID: 29509745
[No Abstract] [Full Text] [Related]
2. Driving CARs on the Highway to Solid Cancer: Some Considerations on the Adoptive Therapy with CAR T Cells.
Abken H
Hum Gene Ther; 2017 Nov; 28(11):1047-1060. PubMed ID: 28810803
[TBL] [Abstract][Full Text] [Related]
3. Driving cars to the clinic for solid tumors.
Castellarin M; Watanabe K; June CH; Kloss CC; Posey AD
Gene Ther; 2018 Jun; 25(3):165-175. PubMed ID: 29880908
[TBL] [Abstract][Full Text] [Related]
4. CAR T Cell Therapy for Solid Tumors.
Newick K; O'Brien S; Moon E; Albelda SM
Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
[TBL] [Abstract][Full Text] [Related]
5. Moving from tinkering in the garage to assembly line production: the manufacture of genetically modified T cells expressing chimeric antigen receptors (CARs) comes on line.
Cooper LJ
Cancer Gene Ther; 2015 Mar; 22(2):64-6. PubMed ID: 25675874
[No Abstract] [Full Text] [Related]
6. From the guest editor: The rise of CAR therapy: the CD19 paradigm, and beyond. Introduction.
Sadelain M
Cancer J; 2014; 20(2):105-6. PubMed ID: 24667953
[No Abstract] [Full Text] [Related]
7. Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy.
Huang Y; Li D; Qin DY; Gou HF; Wei W; Wang YS; Wei YQ; Wang W
Gene Ther; 2018 Jun; 25(3):192-197. PubMed ID: 28820501
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of chimeric antigen receptor T cells may be impaired by prior chemotherapy.
Printz C
Cancer; 2018 Jul; 124(14):2877. PubMed ID: 29975408
[No Abstract] [Full Text] [Related]
9. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
Di S; Li Z
Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers.
Prasad V
Nat Rev Clin Oncol; 2018 Jan; 15(1):11-12. PubMed ID: 28975930
[No Abstract] [Full Text] [Related]
11. Driving CARs Across New Borders.
Turtle CJ; Adair JE
Hum Gene Ther; 2018 May; 29(5):529. PubMed ID: 29715075
[No Abstract] [Full Text] [Related]
12. Driving CARs: as 'living drugs', T cell therapies face dose standardization woes.
Chakradhar S
Nat Med; 2015 Nov; 21(11):1236-8. PubMed ID: 26540379
[No Abstract] [Full Text] [Related]
13. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
Jindal V; Arora E; Gupta S
Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801
[TBL] [Abstract][Full Text] [Related]
14. Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.
Li F; Zhang T; Cao L; Zhang Y
Curr Stem Cell Res Ther; 2018; 13(5):327-335. PubMed ID: 29676233
[TBL] [Abstract][Full Text] [Related]
15. Engineering CAR T Cells with Biomaterials.
Cancer Discov; 2017 Jul; 7(7):656-657. PubMed ID: 28500027
[TBL] [Abstract][Full Text] [Related]
16. Regional Infusion of Chimeric Antigen Receptor T Cells to Overcome Barriers for Solid Tumor Immunotherapy.
Hardaway JC; Prince E; Arepally A; Katz SC
J Vasc Interv Radiol; 2018 Jul; 29(7):1017-1021.e1. PubMed ID: 29935783
[No Abstract] [Full Text] [Related]
17. Next Steps in the CAR Journey of a Thousand Miles.
Brenner MK
Mol Ther; 2017 Oct; 25(10):2226-2227. PubMed ID: 28939089
[No Abstract] [Full Text] [Related]
18. Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer.
Hombach AA; Abken H
Immunotherapy; 2013 Jul; 5(7):677-81. PubMed ID: 23829616
[No Abstract] [Full Text] [Related]
19. Armed T cells with CAR for cancer immunotherapy.
Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):331-2. PubMed ID: 27080712
[No Abstract] [Full Text] [Related]
20. CAR-T field booms as next-generation platforms attract big players.
Morrison C
Nat Biotechnol; 2015 Jun; 33(6):571-2. PubMed ID: 26057954
[No Abstract] [Full Text] [Related]
[Next] [New Search]
